Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 5/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8225046 | 1.00 | REN (0.34) | RENBACE1RORCKMT2ATSHR | |
| SCHEMBL8005033 | 0.89 | REN (0.33) | RENBACE1 | |
| SCHEMBL4501011 | 0.86 | REN (0.33) | RENRORCKMT2ATSHR | |
| SCHEMBL8228289 | 0.86 | KMT2A (0.36) | RENRORCKMT2ATSHR | |
| SCHEMBL8001171 | 0.86 | KMT2A (0.36) | RENRORCKMT2ATSHR | |
| SCHEMBL8002303 | 0.86 | KMT2A (0.36) | RENRORCKMT2ATSHR | |
| SCHEMBL8004948 | 0.84 | REN (0.35) | RENBACE1RORCKMT2ATSHR | |
| SCHEMBL8001572 | 0.83 | KMT2A (0.35) | RENBACE1RORCKMT2ATSHR | |
| SCHEMBL13601245 | 0.83 | KMT2A (0.35) | RENBACE1RORCKMT2ATSHR | |
| SCHEMBL8005030 | 0.82 | REN (0.32) | RENBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| WO-2009106599-A2 | SUBSTITUTED PIPERIDINES AS THERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | REN, AGTR1, AGTR2 | REN 1/4885BACE1 1580/4885RORC 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.